A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.

Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

Discover a study on psoriasis treatment failure, highlighting when to move from topical therapies to systemic care for ...

Pivoting to GLP-1 RAs, Soung explained that they both decrease appetite and food cravings and are very different from the weight loss drugs of the past in terms of how they work, the fact that they ...

A recent Phase 3 clinical trial demonstrated that a steroid-free topical foam, roflumilast (Zoryve), significantly improved the signs and symptoms of psoriasis on both the scalp and body. The foam ...

Genital psoriasis is common in psoriasis patients and shouldn't cause shame or interfere with your sex life, says ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, announces ...

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. The recent cavalcade of biotech deals continued Friday morning, when Bristol Myers Squibb said it had agreed to ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...